Frequency (n) and proportion of the total population (%) of concordance/discordance between BOR assessed by RECIST 1.1 and irBOR assessed by irRECIST
| irBOR by irRECIST, n (%) | BOR by RECIST 1.1, n (%) | |||||
| CR | PR | SD | PD | NE | Overall | |
| irCR | 42 (2.4) | 3 (0.2)† | 2 (0.1)† | 1 (<0.1)* | 0 | 48 (2.7) |
| irPR | 1 (<0.1)† | 172 (9.7) | 8 (0.5) | 11 (0.6) | 0 | 192 (10.9) |
| irSD | 0 | 0 | 592 (33.5) | 135 (7.6) | 0 | 727 (41.2) |
| irPD | 0 | 0 | 0 | 530 (30.0) | 4 (0.2) | 534 (30.3) |
| irNE | 0 | 0 | 0 | 62 (3.5) | 202 (11.4) | 264 (15.0) |
| Overall | 43 (2.4) | 175 (9.9) | 602 (34.1) | 739 (41.9) | 206 (11.7) | 1765 (100) |
The discordant subgroup (a BOR assessment of PD or NE and an irBOR assessment of disease control, ie, irSD or better) is shown: of patients with PD, 135 had irSD, 11 had irPR, and 1 had irCR (n=147).
*This patient had pseudoprogression; the patient initially had disease progression (PD by RECIST) and later had a CR (irCR).
†Due to data errors by the investigator in the assessment of BOR by RECIST 1.1.
BOR, best overall response; CR, complete response; irBOR, immune-related BOR; irCR, immune-related CR; irNE, immune-related NE; irPD, immune-related PD; irPR, immune-related PR; irRECIST, immune-related RECIST; irSD, immune-related SD; NE, not evaluable; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.